Manhattan Research (New York), which has carved out a proprietary space in use of digital media by healthcare providers, released its 2012 Taking the Pulse survey in May; for the first time, the surveying company did all its work online, with no telephone queries, “due to the near ubiquitous online access among US physicians.”
Highlights of the survey are: the meteoric rise of the interactive tablet (primarily, the Apple iPad), now owned or used for professional purposes by 62% of physicians; and a surprising flattening of interest in social media sites for clinical consulting (common among only 7% of physicians), while traditional telephone interactions or face-to-face meetings are the medium of engagement for 81% and 64% of physicians, respectively. Manhattan Research concludes that for social media channels, there is a “low value proposition” and “privacy concerns [are] still a barrier,” according to Monique Levy, VP of research for the company.
Along with the growth of tablet usage, the “three screen” physician is now common: making use of a desktop/laptop; a smartphone; or a tablet. Somewhat surprisingly, one device does not cannibalize another; the more screens physicians use, the more time they spend online.
JOURNALS, COLLEAGUES ARE THE LEADING INFLUENCES ON CLINICAL DECISIONS. credit: Manhattan Research
Information influence
Manhattan Research also polled respondents broadly about their informational influences on clinical decisions (see Figure). As can be expected, peer interactions with colleagues (mostly offline) is the dominant source, both in frequency and in influence. But professional journals (online or offline) are quite high. Pharma reps are strong in reach, but less so in influence. Continuing medical education (CME) and conferences (online and offline) are average influencers, with CME providing more reach.
Within the subset of online learning, Manhattan Research finds that physicians are avid users of online video, especially for CME, online lectures, and disease or condition information. The top destinations for accessing professional videos are WebMD Professional Network, YouTube, QuantiaMD, pharma industry sites, and professional associations.
Taking the Pulse is one part of a comprehensive polling and analytical service from the company; the data are subdivided by physician specialties, and by hardware platforms. Other surveys look at therapeutic segmentations, consumer activities and geographic variations.
Social media sites are stuck on a plateau among physicians
Latest Manhattan Research market study finds little growth in social media usage; also, the rise of the 'three screen' physician
Manhattan Research (New York), which has carved out a proprietary space in use of digital media by healthcare providers, released its 2012 Taking the Pulse survey in May; for the first time, the surveying company did all its work online, with no telephone queries, “due to the near ubiquitous online access among US physicians.”
Highlights of the survey are: the meteoric rise of the interactive tablet (primarily, the Apple iPad), now owned or used for professional purposes by 62% of physicians; and a surprising flattening of interest in social media sites for clinical consulting (common among only 7% of physicians), while traditional telephone interactions or face-to-face meetings are the medium of engagement for 81% and 64% of physicians, respectively. Manhattan Research concludes that for social media channels, there is a “low value proposition” and “privacy concerns [are] still a barrier,” according to Monique Levy, VP of research for the company.
Along with the growth of tablet usage, the “three screen” physician is now common: making use of a desktop/laptop; a smartphone; or a tablet. Somewhat surprisingly, one device does not cannibalize another; the more screens physicians use, the more time they spend online.
JOURNALS, COLLEAGUES ARE THE LEADING INFLUENCES ON CLINICAL DECISIONS. credit: Manhattan Research
Information influence
Manhattan Research also polled respondents broadly about their informational influences on clinical decisions (see Figure). As can be expected, peer interactions with colleagues (mostly offline) is the dominant source, both in frequency and in influence. But professional journals (online or offline) are quite high. Pharma reps are strong in reach, but less so in influence. Continuing medical education (CME) and conferences (online and offline) are average influencers, with CME providing more reach.
Within the subset of online learning, Manhattan Research finds that physicians are avid users of online video, especially for CME, online lectures, and disease or condition information. The top destinations for accessing professional videos are WebMD Professional Network, YouTube, QuantiaMD, pharma industry sites, and professional associations.
Taking the Pulse is one part of a comprehensive polling and analytical service from the company; the data are subdivided by physician specialties, and by hardware platforms. Other surveys look at therapeutic segmentations, consumer activities and geographic variations.
Trade & Channel Strategies 2024: Lessons Learned and Considerations with Humira
A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.
Incorporating AI into Commercialization Plans
Steve Silvestro explains the value of artificial intelligence in launch plans, benefits to integrating DTC and HCP marketing strategies, and more.
Going Inside the Gross-to-Net Bubble and Its Nuances
A crash course on the bubble itself, including therapeutic areas most affected.
Toripalimab Launches in India
Dr. Reddy’s immuno-oncology drug for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma will be marketed under the brand name Zytorvi.
PTC Therapeutics, Novartis Sign License and Collab Deal for Huntington’s Disease Program
The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.
Trade & Channel Strategies 2024: Lessons Learned and Considerations with Humira
A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.
Incorporating AI into Commercialization Plans
Steve Silvestro explains the value of artificial intelligence in launch plans, benefits to integrating DTC and HCP marketing strategies, and more.
Going Inside the Gross-to-Net Bubble and Its Nuances
A crash course on the bubble itself, including therapeutic areas most affected.
Toripalimab Launches in India
Dr. Reddy’s immuno-oncology drug for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma will be marketed under the brand name Zytorvi.
PTC Therapeutics, Novartis Sign License and Collab Deal for Huntington’s Disease Program
The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.